Skip to content
TrialScanner

NCT03340675

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

Phase 2CompletedCPIXLead

Registry record

Lead sponsor
Cumberland Pharmaceuticals
Conditions
Duchenne Muscular Dystrophy Cardiomyopathy; Cardiomyopathy, Dilated
Primary completion
Mar 6, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03340675 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03340675: Oral Ifetroban in Subjects... | TrialScanner